Skip to main content
    B

    Bristol-Myers Squibb Company (BMY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $62.94
    -0.49 (-0.77%)

    Market Cap: $129.66B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Bristol-Myers Squibb Company (BMY) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Bristol-Myers Squibb Company (BMY) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Bristol-Myers Squibb Company reported EPS of $1.35, above the $1.21 estimate. It beat the EPS estimate in each of the last 10 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    88%(35/40)
    Avg Surprise
    +8.74%
    Streak
    10 Q

    Upcoming Estimates

    Reports Feb 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.50
    Range$1.29 - $1.69
    25 analysts
    Revenue Consensus
    $12.80B
    Range$12.17B - $13.68B
    23 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$1.52
    Range$1.31 - $1.68
    9 analysts
    EPS Revisions
    3
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$1.45+5.0%
    60d ago$1.45+5.0%
    30d ago$1.47+3.3%
    7d ago$1.51+0.5%
    Current$1.52
    Revenue Consensus
    $11.17B
    Range$10.64B - $11.37B
    6 analysts

    Next Report

    BMY has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 19.0% above the $1.26 reported for the quarter ended Dec 31, 2025.

    BMY Earnings Call

    The latest BMY earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, BMY beat 35 and missed 5. Revenue for the quarter ended Sep 30, 2026 was $13.07B, up 7.0% from $12.22B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.35$1.21$0.98 - $1.75+11.57%Beat-17.2%231 up, 8 downOct 29, 2026$13.07B
    Jun 30, 2026$2.04$1.59$1.48 - $1.68+28.30%Beat+39.7%230 up, 3 downJul 30, 2026$12.97B
    Mar 31, 2026$1.58$1.42$1.23 - $1.53+11.27%Beat-12.2%245 up, 11 downApr 30, 2026$11.49B
    Dec 31, 2025$1.26$1.20$0.88 - $1.66+5.00%Beat-24.6%200 up, 14 downFeb 5, 2026$12.50B
    Sep 30, 2025$1.63$1.52$1.35 - $1.74+7.24%Beat-9.4%211 up, 13 downOct 30, 2025$12.22B
    Jun 30, 2025$1.46$1.10$0.96 - $1.67+32.73%Beat-29.5%211 up, 14 downJul 31, 2025$12.27B
    Mar 31, 2025$1.80$1.50$1.42 - $1.63+20.00%BeatN/A202 up, 6 downApr 24, 2025$11.20B
    Dec 31, 2024$1.67$1.47$1.41 - $1.60+13.61%Beat+5.0%206 up, 6 downFeb 6, 2025$12.34B
    Sep 30, 2024$1.80$1.50$1.38 - $1.62+20.00%Beat-10.0%181 up, 1 downOct 31, 2024$11.89B
    Jun 30, 2024$2.07$1.63$1.52 - $1.76+26.99%Beat+18.3%176 up, 2 downJul 26, 2024$12.20B
    Mar 31, 2024-$4.40-$4.14-$4.78 - -$3.27-6.28%Miss-314.6%170 up, 4 downApr 25, 2024$11.87B
    Dec 31, 2023$1.59$1.43$1.38 - $1.76+11.19%Beat-12.6%170 up, 4 downFeb 2, 2024$11.48B
    Sep 30, 2023$2.00$1.77$1.67 - $1.86+12.99%Beat+0.5%182 up, 1 downOct 26, 2023$10.97B
    Jun 30, 2023$1.75$1.99$1.86 - $2.04-12.06%Miss-9.3%204 up, 3 downJul 27, 2023$11.23B
    Mar 31, 2023$2.05$1.97$1.87 - $2.07+4.06%Beat+4.6%193 up, 3 downApr 27, 2023$11.34B
    Dec 31, 2022$1.82$1.73$1.61 - $1.83+5.20%Beat-0.5%186 up, 1 downFeb 2, 2023$11.41B
    Sep 30, 2022$1.99$1.83$1.74 - $1.91+8.74%Beat-0.5%164 up, 0 downOct 25, 2022$11.22B
    Jun 30, 2022$1.93$1.80$1.68 - $1.93+7.22%Beat0.0%161 up, 3 downJul 27, 2022$11.89B
    Mar 31, 2022$1.96$1.90$1.74 - $1.97+3.16%Beat+12.6%163 up, 4 downApr 29, 2022$11.65B
    Dec 31, 2021$1.83$1.80$1.73 - $1.85+1.67%Beat+25.3%172 up, 3 downFeb 4, 2022$11.98B
    Sep 30, 2021$2.00$1.92$1.86 - $2.02+4.17%Beat+22.7%12N/AOct 27, 2021$11.62B
    Jun 30, 2021$1.93$1.90$1.81 - $2.00+1.58%Beat+18.4%13N/AJul 28, 2021$11.70B
    Mar 31, 2021$1.74$1.81$1.70 - $1.96-3.87%Miss+1.2%13N/AApr 29, 2021$11.07B
    Dec 31, 2020$1.46$1.42$1.35 - $1.60+2.82%Beat+19.7%14N/AFeb 4, 2021$11.07B
    Sep 30, 2020$1.63$1.49$1.43 - $1.57+9.40%Beat+39.3%14N/ANov 5, 2020$10.54B
    Jun 30, 2020$1.63$1.48$1.38 - $1.62+10.14%Beat+38.1%12N/AAug 6, 2020$10.13B
    Mar 31, 2020$1.72$1.45$1.38 - $1.57+18.62%Beat+56.4%11N/AMay 7, 2020$10.78B
    Dec 31, 2019$1.22$1.16N/A+5.17%Beat+29.8%4N/AFeb 6, 2020$7.95B
    Sep 30, 2019$1.17$1.07$1.03 - $1.14+9.35%Beat+7.3%10N/AOct 31, 2019$6.01B
    Jun 30, 2019$1.18$1.06$1.03 - $1.09+11.32%Beat+16.8%10N/AJul 25, 2019$6.27B
    Mar 31, 2019$1.10$1.08$1.05 - $1.16+1.85%Beat+17.0%11N/AApr 25, 2019$5.92B
    Dec 31, 2018$0.94$0.85$0.80 - $0.95+10.59%Beat+38.2%11N/AJan 24, 2019$5.97B
    Sep 30, 2018$1.09$0.91$0.86 - $0.96+19.78%Beat+45.3%14N/AOct 25, 2018$5.69B
    Jun 30, 2018$1.01$0.87$0.84 - $0.91+16.09%Beat+36.5%14N/AJul 26, 2018$5.70B
    Mar 31, 2018$0.94$0.85$0.79 - $0.92+10.59%Beat+11.9%17N/AApr 26, 2018$5.19B
    Dec 31, 2017$0.68$0.67$0.63 - $0.72+1.49%Beat+7.9%19N/AFeb 5, 2018$5.45B
    Sep 30, 2017$0.75$0.77$0.72 - $0.81-2.60%Miss-2.6%19N/AOct 26, 2017$5.25B
    Jun 30, 2017$0.74$0.73$0.70 - $0.78+1.37%Beat+7.2%18N/AJul 27, 2017$5.14B
    Mar 31, 2017$0.84$0.74N/A+13.51%Beat+13.5%N/AN/AApr 27, 2017$4.93B
    Dec 31, 2016$0.63$0.66N/A-4.55%Miss+65.8%N/AN/AJan 26, 2017$5.24B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $6.15, up 439.5% from the year before. It was $2.83 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$6.15+439.5%
    Dec 31, 2024$1.14-84.6%
    Dec 31, 2023$7.39-4.0%
    Dec 31, 2022$7.70+2.7%
    Dec 31, 2021$7.50+16.5%
    Dec 31, 2020$6.44+37.9%
    Dec 31, 2019$4.67+17.3%
    Dec 31, 2018$3.98+32.2%
    Dec 31, 2017$3.01+6.4%
    Dec 31, 2016$2.83N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,200 words across 20 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,17320
    2026Q2Jun 30, 20267,47319
    2026Q1Mar 31, 20267,77117
    2025Q4Dec 31, 20259,61019
    2025Q3Sep 30, 20259,03120
    2025Q2Jun 30, 20259,57819
    2025Q1Mar 31, 20259,45725
    2024Q4Dec 31, 202412,55726

    2026Q3 Earnings Call

    Opening remarks

    Charles E. Triano Senior Vice President and Head of Investor Relations Thank you, and good morning, everyone. We appreciate you joining our third quarter 2026 earnings call. With me this morning for prepared remarks are Christopher S. Boerner, our Board Chair and Chief Executive Officer, and David V. Elkins, our Chief Financial Officer. Also participating in today's call are Adam Lenkowsky, our Chief Commercialization Officer, and Cristian Massacesi, our Chief Medical Officer and Head of Global Drug Development. Earlier this morning, we posted our quarterly slide presentation to bms.com, which you can use to follow along with Christopher and David's remarks. Before we get started, I will remind everybody that during this call, we will make statements about the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in the company's SEC filings. These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date. We specifically disclaim any obligation to update forward-looking statements, even if our estimates change. We will also focus our comments on our non-GAAP financial measures, which are adjusted to exclude certain specified items. Reconciliations of certain non-GAAP financial measures to the most comparable GAAP measure are available at bms.com. Finally, unless otherwise stated, all comparisons are made with the same period in 2025, and sales growth rates will be discussed on an underlying basis, which excludes the impact of foreign exchange. All references to our P&L are on a non-GAAP basis. With that, I will hand it over to Christopher.

    Christopher S. Boerner Board Chair and Chief Executive Officer Thanks, Chuck. Good morning, everyone, and thank you for joining our Q3 2026 earnings call. We reported another quarter of double-digit growth in our growth portfolio and progressed our plans to de-risk the pipeline to position the company for long-term success. We have seen several positive registrational readouts and regulatory approvals over the past few months, and we expect more to come, bringing the next wave of launches into sharper focus. We are executing well commercially, our differentiated pipeline is advancing nicely, and we continue to operate with discipline, which gives us strategic flexibility to invest for sustainable growth. Based on the strength of our results, we are raising our full-year guidance. David will provide additional details on this shortly. Let me start with our Q3 performance on Slide 4. Our growth portfolio continues to deliver solid results, with sales increasing 12%, driven by a broad set of differentiated products. We generated strong performance in key brands, including Reblozyl, Breyanzi, Opdualag, Qvantig, and Camzyos. We also continue to expand the reach of our medicines.

    Frequently Asked Questions About BMY

    When is Bristol-Myers Squibb Company's next earnings date?

    Bristol-Myers Squibb Company's next earnings report is expected for Feb 3, 2027.

    Did BMY beat earnings estimates last quarter?

    Yes. Bristol-Myers Squibb Company reported EPS of $1.35 for the quarter ended Sep 30, 2026, above the $1.21 estimate, a 11.57% surprise.

    What EPS do analysts expect from BMY next quarter?

    The consensus EPS estimate for Bristol-Myers Squibb Company for the quarter ending Dec 31, 2026 is $1.50 from 25 analysts, with estimates from $1.29 to $1.69.

    How often does BMY beat earnings estimates?

    Bristol-Myers Squibb Company beat the EPS estimate in each of the last 10 quarters, with an average surprise of +17.67%.